Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Outlook Highlighting Key Drivers And Market Evolution
The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
From Its 2026 Market Size, What Value Is The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Projected To Reach By 2030?
The exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market has experienced robust growth in recent years. This market is projected to expand from $6.11 billion in 2025 to $6.55 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 7.1%. Its historical growth can be attributed to elements such as the increasing prevalence of chronic pancreatitis, a heightened awareness of digestive disorders, limited access to specialized diagnostics, the adoption of nutritional supplements, and the expansion of home healthcare services.
The exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market is projected to experience substantial expansion over the coming years. This market is anticipated to reach a valuation of $8.97 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.2%. The projected increase during this period is driven by progress in personalized enzyme therapies, the incorporation of AI into diagnostics, an increasing need for non-invasive imaging, the widening availability of telehealth services, and a heightened emphasis on patient-focused nutritional management. Key trends expected during the forecast timeframe encompass sophisticated pancreatic enzyme replacement therapies, point-of-care diagnostic options, tailored nutritional management plans, non-invasive imaging methods for EPI, and the integration of telehealth into EPI management.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12992&type=smp
What Significant Factors Are Influencing The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Expansion?
The anticipated rise in the number of individuals suffering from diabetes is projected to fuel the expansion of the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market. Diabetes is defined as a long-term metabolic ailment characterized by persistently elevated blood sugar levels (hyperglycemia), stemming from the body’s inability to synthesize sufficient insulin or its inefficient utilization. EPI treatment, specifically pancreatic enzyme replacement therapy (PERT), is effective in enhancing nutrient absorption and can also improve glycemic control for those with both diabetes and EPI. For example, in June 2024, data from The National Health Service (NHS England), a publicly funded UK healthcare system, revealed that in 2023, the count of individuals identified with pre-diabetes by the NHS in England increased to 3,615,330, representing an 18% surge from 3,065,825 in 2022. Furthermore, among individuals below 40 years old, cases saw a nearly 25% rise, escalating from 173,166 in 2022 to 216,440 in 2023. Consequently, the growing population affected by diabetes is a significant force driving the growth of the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market. The increasing occurrence of gastrointestinal illnesses is expected to stimulate the growth of the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market in the future. Gastrointestinal diseases encompass a range of medical conditions impacting the digestive system, which includes the organs vital for food processing. These therapeutics and diagnostics for Exocrine pancreatic insufficiency (EPI) are essential for managing gastrointestinal diseases by addressing underlying enzyme deficiencies and facilitating proper nutrient digestion. As an illustration, in June 2023, Crohn’s and Colitis Canada, a non-profit organization based in Canada, estimated that over 322,600 Canadians were living with inflammatory bowel diseases (IBD) in 2023, constituting approximately 0.82% of the population. With the ongoing spread of IBD, it is predicted that around 470,000 Canadians will be affected by IBD by 2035, amounting to roughly 1.1% of the population, or 1 in every 91 people in the country. Thus, the escalating incidence of gastrointestinal diseases is poised to boost the growth of the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market.
How Are Segments Identified Within The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Segment Framework?
The exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market covered in this report is segmented –
1) By Therapies: Nutritional Management, Pancreatic Enzyme Replacement Therapy (PERT), Lifestyle Modifications Approach
2) By Diagnostics: Blood Tests, Magnetic Resonance Imaging (MRI), Endoscopic Ultra-Sonography (EUS), Computerized Tomography (CT) Scanning
3) By Drug Type: Generic, Branded
4) By Distribution Channel: Direct Tender, Retail Pharmacy , Third-Party Distributor, Other Distribution Channels
5) By End User: Hospitals, Specialty Clinics, Homecare, Diagnostic Center, Research And Academic Institutes, Other End Users
Subsegments:
1) By Nutritional Management: Dietary Modifications, Nutritional Supplements
2) By Pancreatic Enzyme Replacement Therapy (PERT): Capsule Formulations, Tablet Formulations, Powder Formulations
3) By Lifestyle Modifications Approach: Weight Management, Physical Activity Recommendations, Smoking Cessation Programs
Which Trends Are Impacting The Progress Of The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market?
Leading companies active in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market are employing a strategic partnership strategy to boost technology integration and expand their market reach. A strategic partnership typically denotes a collaborative relationship between two or more entities, where they combine their assets, expertise, and endeavors to achieve shared goals or objectives. For instance, in February 2023, Codexis, Inc., a US-based protein engineering company, along with Nestlé Health Science, a Switzerland-based science of nutrition, disclosed preliminary results from their Phase 1 clinical trial of CDX-7108, an experimental therapy designed to treat exocrine pancreatic insufficiency (EPI). The outcomes from this Phase 1 trial set the stage for further studies that could significantly enhance treatment options for patients affected by EPI.
Who Are The Companies Competing Within The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market?
Major companies operating in the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market are Abbott Laboratories, Metagenics LLC, Chiesi Farmaceutici S.p.A., Nordmark Arzneimittel GmbH & Co. KG, Digestive Care Inc., Bioserv Diagnostics Gmbh, Aptalis Pharma Inc., EagleBiosciences Inc., ScheBo Biotech AG, Solvay S.A., Codexis Inc., ChiRhoClin Inc., Alcresta Therapeutics Inc., Cilian AG, First Wave BioPharma Inc., Laboratory Corporation of America Holdings, Organon, Vivus Inc., Anthera Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd
Get The Full Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Report:
Which Region Dominates The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market By Market Share?
North America was the largest region in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market in 2025. The regions covered in the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market 2026, By The Business Research Company
Exocrine Pancreatic Insufficiency Epi Therapeutics And Diagnostics Market Report 2026
Exocrine Pancreatic Insufficiency Market Report 2026
Acute Pancreatitis Market Report 2026
https://www.thebusinessresearchcompany.com/report/acute-pancreatitis-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
